product name Pemirolast potassium
Description: Pemirolast potassium (also known as BMY 26517) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent. It is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma. Pemirolast potassium inhibits chemical mediator release from tissue mast cells and is also shown to inhibit the release of peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP) from sensory nerves
References: Ann Allergy. 1992 Jun;68(6):488-91; Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62.
266.3
Formula
C10H7N6O.K
CAS No.
100299-08-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 53 mg/mL (199.0 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
BMY26517
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19427890
| In Vitro |
In vitro activity: Pemirolast potassium (BMY 26517) is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma. Pemirolast potassium (BMY 26517) inhibits chemical mediator release from tissue mast cells and is also shown to inhibit the release of peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP) from sensory nerves. Pemirolast potassium is used for the treatment of allergic conjunctivitis and prophylaxis for pulmonary hypersensitivity reactions to drugs such as paclitaxel. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Pemirolast potassium (BMY 26517) reduces kaolin intake by inhibition of substance P release in rats. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. |
| Animal model | |
| Formulation & Dosage | |
| References | Ann Allergy. 1992 Jun;68(6):488-91; Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62. |
